Travocort: isoconazole & diflucortolone 21-valerate combination [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133140 |
| MeSH ID | M0074298 |
| Synonym |
|---|
| pregna-1,4-diene-3,20-dione, 6,9-difluoro-11-hydroxy-16-methyl-21-((1-oxopentyl)oxy)-, (6alpha,11beta,16alpha)-, mixt. with 1-(2-(2,4-dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)-1h-imidazole mononitrate |
| travocort |
| 78940-01-9 |
| 1-[2-(2,4-dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]imidazole;[2-[(6s,8s,10s,11s,13s,14s,16r,17s)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-7,8,11,12,14,15,16,17-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] pentanoate;nitric |
Travocort is a combination of 1% isoconazole nitrate (ISN) and 0.1% diflucortolone valerate (DFV) It is a potent topical corticosteroid with low systemic absorption and therefore a low risk of systemic glucocorticoid side-effects.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Travocort is a combination of 1% isoconazole nitrate (ISN), a broad-spectrum imidazole with established antimicrobial activity and antimycotic efficacy, and 0.1% diflucortolone valerate (DFV), a potent topical corticosteroid with low systemic absorption and therefore a low risk of systemic glucocorticoid side-effects." | ( The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses. Friedrich, M; Havlickova, B, 2008) | 1.07 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The rapid improvement observed with Travocort treatment, combined with favourable safety and tolerability, results in higher patient satisfaction, and therefore, can be an effective tool to increase treatment adherence in patients with dermatomycoses accompanied by inflammatory signs and symptoms." | ( Isoconazole nitrate: a unique broad-spectrum antimicrobial azole effective in the treatment of dermatomycoses, both as monotherapy and in combination with corticosteroids. Veraldi, S, 2013) | 0.66 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Studies show, however, that the addition of a topical corticosteroid to imidazole therapy increases the bioavailability and prolongs the activity of the antimycotic, while rapidly reducing inflammatory symptoms." | ( The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses. Friedrich, M; Havlickova, B, 2008) | 0.35 |
| " Isoconazole nitrate (ISN) is a broad-spectrum antimicrobial agent with a highly effective antimycotic and gram-positive antibacterial activity, a rapid rate of absorption and low systemic exposure potential." | ( Isoconazole nitrate: a unique broad-spectrum antimicrobial azole effective in the treatment of dermatomycoses, both as monotherapy and in combination with corticosteroids. Veraldi, S, 2013) | 0.39 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (89.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (9.52%) | 5.53% |
| Reviews | 2 (9.52%) | 6.00% |
| Case Studies | 14 (66.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (14.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||